Drugs / Tetrahydrocannabivarin
Tetrahydrocannabivarin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT05574049 Comparator | Jan → May 2022 | hyperglycemia, hyperlipidemia, metabolic syndrome X, morbid obesity | Medical Life Care Planners, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02053272 Comparator | Feb 2014 → Feb 2016 | type 2 diabetes mellitus | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01491490 Comparator | Oct 2011 → Oct 2012 | schizophrenia | GW Research Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT01217112 Comparator | Oct 2010 → May 2012 | hyperlipidemia, type 2 diabetes mellitus | Jazz Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetrahydrocannabivarin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05574049 ↗ |
| Known as | .delta.9-tetrahydrocannabivarin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2387541 ↗ |
| Known as | GWP42004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01217112 ↗ |
| Known as | O-4394 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2387541 ↗ |
| Known as | THCV | ChEMBL registry synonym — accepted as the source's own label CHEMBL2387541 ↗ |
| Modality | Small molecule | — CHEMBL2387541 ↗ |
| Route | Oral | “5 mg capsules, PO, BD, 91 days” NCT01217112 ↗ |